Dheeraj Aggarwal, CFO, Venus Remedies is especially ecstatic about bagging the marketing rights for Meropenem in Gulf, Saudi Arabia as the company would be the first generic player there.
first published: Dec 6, 2013 03:48 pm
A collection of the most-viewed Moneycontrol videos.
Live: Can Nifty extend gains and reclaim 26,000? | Opening Bell
FSS Simply Payments 2025 | AI in Payments: Building a Governance-First Future.
Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell
Live: Can Nifty snap 3-day losing streak after Fed's policy outcome? | Opening Bell
